| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
receptor protein tyrosine phosphatase (RPTPβ/ζ)[1]
RPTPbeta/zeta (receptor protein tyrosine phosphatase beta/zeta). MY10 is a potent and orally active inhibitor of RPTPbeta/zeta, blocking its phosphatase activity and thereby enhancing downstream signaling pathways such as c-Met tyrosine phosphorylation. |
|---|---|
| ln Vitro |
MY10 inhibits RPTPbeta/zeta activity in vitro, leading to activation of c-Met tyrosine phosphorylation. It reduces NF-kappaB p65 expression and prevents alcohol-induced downregulation of Ptprz1 and Alk expression. These molecular changes contribute to its effects on ethanol consumption and reward-related behaviors in preclinical models.
|
| ln Vivo |
In vivo, MY10 (administered orally) attenuates binge-like ethanol consumption and reduces the rewarding effects of ethanol in animal models. By inhibiting RPTPbeta/zeta and modulating NF-kappaB and c-Met signaling, it decreases alcohol-seeking behavior and prevents alcohol-induced neuroinflammation. This makes MY10 a promising tool for studying alcohol use disorders.
|
| Enzyme Assay |
For non-cellular assays, purified RPTPbeta/zeta enzyme is incubated with a fluorogenic phosphopeptide substrate (e.g., END-pY-INLE) or DiFMUP in assay buffer. MY10 is added at varying concentrations (0.1-100 uM). Phosphate release is measured by fluorescence (excitation 360 nm, emission 460 nm) or by a malachite green-based colorimetric assay to calculate IC50 values.
|
| Cell Assay |
For cell-based assays, neurons or RPTPbeta/zeta-expressing cell lines are treated with MY10 (0.5-50 uM) for 1-24 hours. c-Met tyrosine phosphorylation is measured by immunoprecipitation and Western blot using phospho-specific antibodies. NF-kappaB p65 expression is quantified by Western blot or immunofluorescence. Cells may be exposed to alcohol (e.g., 50 mM ethanol) to model alcohol-induced changes.
|
| Animal Protocol |
For animal studies, MY10 is administered orally to mice in binge-like ethanol consumption models (e.g., Drinking-in-the-Dark paradigm). Doses typically range from 30-100 mg/kg. Ethanol intake and preference are measured over 2-4 hours. Conditioned place preference (CPP) tests assess ethanol reward. Brain tissue is harvested for analysis of Ptprz1 and Alk expression, c-Met phosphorylation, and neuroinflammation markers (NF-kappaB, IL-6, TNF-alpha).
|
| ADME/Pharmacokinetics |
MY10 is orally bioavailable with favorable pharmacokinetic properties. It is typically formulated in a vehicle such as 0.5% methylcellulose or 10% DMSO, 40% PEG300, 5% Tween-80, and 45% saline for oral administration. The half-life and other PK parameters are likely reported in the literature. The molecular weight is 384.36.
|
| Toxicity/Toxicokinetics |
Toxicological data for MY10 are limited to preclinical studies. At therapeutic doses (30-100 mg/kg in mice), no significant systemic toxicity or body weight loss has been reported. Standard safety precautions for handling research chemicals should be followed. It is not intended for human use without further development.
|
| References | |
| Additional Infomation |
MY10 (CAS: 2204270-73-3) has a molecular formula of C15H10F6OS2 and a molecular weight of 384.36. It is a potent and orally active RPTPbeta/zeta inhibitor that attenuates binge-like ethanol consumption and ethanol reward. It is a valuable tool for studying the neurobiology of alcohol use disorders and the role of RPTPbeta/zeta in addiction-related behaviors. It is not an approved drug.
|
| Molecular Formula |
C15H10F6OS2
|
|---|---|
| Molecular Weight |
384.359722614288
|
| Exact Mass |
384.007
|
| CAS # |
2204270-73-3
|
| PubChem CID |
145991728
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
371
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C(F)(F)F)C1C=CC(=CC=1)COC1C=CC(=CC=1)SC(F)(F)F
|
| InChi Key |
OJUUGOMDHJFXJH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10F6OS2/c16-14(17,18)23-12-5-1-10(2-6-12)9-22-11-3-7-13(8-4-11)24-15(19,20)21/h1-8H,9H2
|
| Chemical Name |
1-(trifluoromethylsulfanyl)-4-[[4-(trifluoromethylsulfanyl)phenoxy]methyl]benzene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (130.09 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6017 mL | 13.0086 mL | 26.0173 mL | |
| 5 mM | 0.5203 mL | 2.6017 mL | 5.2035 mL | |
| 10 mM | 0.2602 mL | 1.3009 mL | 2.6017 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
